IPP Bureau
Novartis to spin-off Sandoz business to a standalone company
By IPP Bureau - August 28, 2022
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
Moderna files for emergency use of BA.4/BA.5 Omicron booster
By IPP Bureau - August 28, 2022
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Collective efforts needed to make India a global healthcare leader: Dr Mandaviya
By IPP Bureau - August 28, 2022
It is high time that India assumed a leadership role in healthcare.
Philips spotlights integrated, data-driven cardiology solutions at ESC 2022
By IPP Bureau - August 28, 2022
Philips AI-powered interventional and diagnostic smart systems enhances diagnostic confidence, drive greater efficiency, and improve patient outcomes
Glenmark receives OAI from USFDA for Goa facility
By IPP Bureau - August 28, 2022
Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest.
Cipla receives 6 observations from USFDA for Goa facility
By IPP Bureau - August 28, 2022
There are no data integrity (DI) observations.
Syngene International forms a new subsidiary
By IPP Bureau - August 28, 2022
The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind
Syngene International to acquire stake in O2 Renewable Energy II
By IPP Bureau - August 28, 2022
A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power
Aurobindo Pharma Foundation and Rotary Clubs donated 800 bicycles
By IPP Bureau - August 27, 2022
The drive also conducted a mega health camp, cancer screening for women and men, ENT screening for children, and blood donation drive
Benvic acquires specialty U.S. compounder Chemres
By IPP Bureau - August 27, 2022
The ninth acquisition since 2018
Jubilant receives EIR from USFDA for its radiopharmaceuticals manufacturing facility Montreal Canada
By IPP Bureau - August 27, 2022
With the receipt of the EIR, the inspection stands successfully closed.
Lupin receives UK MHRA Approval of Lutio for treatment of COPD
By IPP Bureau - August 27, 2022
Lutio has the potential to offer significant cost savings when available to UK patients.
Lupin launches Desvenlafaxine extended-release tablets in the US
By IPP Bureau - August 27, 2022
Desvenlafaxine Extended-Release Tablets, 25 mg is a generic equivalent of Pristiq Extended-Release Tablets, 25 mg of PF PRISM C.V.
Granules India received ANDA approval for Guaifenesin and Pseudoephedrine Hydrochloride ER
By IPP Bureau - August 27, 2022
Granules now have a total of 51 ANDA approvals from US FDA (49 Final approvals and 2 tentative approvals).
US FDA inspection at Gland Pharma's Dundigal facility, Hyderabad
By IPP Bureau - August 26, 2022
The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.
